Article Image

The opioid crisis in communities

In Ontario alone, about 70% of patients admitted into emergency medical services for opioid toxicity had received an opioid prescription in the previous year.5

The opioid crisis is having devastating effects on individuals, families and communities across Canada; you may have seen the effects in your own community.1 Anyone taking prescribed or illicit opioids is at risk for an overdose (i.e., opioid-induced respiratory depression).2 In fact, between January 2016 and December 2020, there were 24,671 hospitalizations for all opioid-related overdoses; that’s an average of nearly 14 per day.3 In 2020 alone, there were 5,215 hospitalizations for all opioid-related overdoses; 68% of those were accidental.3

The opioid crisis is a complex issue; while illegal drugs have caused many of the opioid-related harms, prescription drugs have also contributed.1 Despite patients intending to take their prescribed medication as instructed, there are a number of factors that can contribute to the risk of patients experiencing an overdose, such as alcohol or sedative use, or certain health conditions.2 With the high prescribing rates of opioids in Canada, many of your patients may be at risk.1 In 2018 alone, almost 1 in 8 Canadians had an opioid prescription.4

The Canadian National Consensus Guidelines for Naloxone Dispensing by Pharmacists recommend that ALL patients receiving an opioid prescription are also provided a take-home naloxone kit as a safety precaution.6,7 The kits are available in either a nasal spray form, like NARCAN® Nasal Spray, or an injection.7

You can help reduce the impact of the opioid crisis. By counselling and providing the necessary information to all your patients taking opioids, you can help reduce the number of opioid-related poisonings in your community.

 

References: 1. Government of Canada. Canada’s Opioid Crisis. Available at: https://www.canada.ca/content/dam/hc-sc/documents/services/publications/healthy-living/canada-opioid-crisis.pdf. Accessed July 27, 2021. 2. Government of Canada. Opioid overdose. Available at: https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/overdose.html. Accessed July 27, 2021. 3. Government of Canada. Federal actions on opioids to date. Available at: https://www.canada.ca/content/dam/hc-sc/documents/services/substance-use/problematic-prescription-drug-use/opioids/responding-canada-opioid-crisis/federal-actions/federal-action-opioids-to-date-june-eng.pdf. Accessed July 27, 2021. 4. Canadian Centre on Substance Use and Addiction. Canadian Drug Summary. July 2020. 5. Gomes, T et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ. 2018;362:k3207. 6. Tsuyuki R et al. Canadian national consensus guidelines for naloxone prescribing by pharmacists. Canadian Pharmacists Journal. 2020;153(6):347-351. 7. Ontario Pharmacists Association. Pharmacist clinical tool for initiating naloxone discussions. Available at: https://opatoday.com/wp-content/uploads/Practice/Tools/Naloxone/Pharmacist-Clinical-Tool-for-Initiating-Naloxone-Discussions.pdf. Accessed July 27, 2021.

PP-NAR4-CA-00087_05-2024 EN

Distributed by Emergent BioSolutions Canada Inc. Mississauga, ON L5N 6M1.

© 2025 Emergent BioSolutions Canada Inc., a wholly owned subsidiary of Emergent BioSolutions Inc.
NARCAN® is a registered trademark of Emergent Operations Ireland Limited, which is a subsidiary of Emergent BioSolutions Inc.

EMERGENT® and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries.